| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach
|
Lavery, Clare
|
|
|
|
4 |
p. 233-245
|
artikel
|
| 2 |
A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment
|
Sullivan, Tim
|
|
|
|
4 |
p. 215-222
|
artikel
|
| 3 |
Biosimilar Uptake: The Importance of Healthcare Provider Education
|
Oskouei, Sonia Tadjalli
|
|
|
|
4 |
p. 215-224
|
artikel
|
| 4 |
Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study
|
Rahalkar, Hasumati
|
|
|
|
4 |
p. 235-251
|
artikel
|
| 5 |
Clinical Quality in Cancer Research: Strategy to Assess Data Integrity of Germline Variants Inferred from Tumor-Only Testing Sequencing Data
|
Ménard, Timothé
|
|
|
|
4 |
p. 225-233
|
artikel
|
| 6 |
Correction to: Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
|
Speers, Marjorie A.
|
|
|
|
4 |
p. 295
|
artikel
|
| 7 |
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
|
Devaraja, K.
|
|
|
|
4 |
p. 269-289
|
artikel
|
| 8 |
Current Status and Challenges of Pharmacovigilance of Traditional Medicines in French-Speaking West African (UEMOA) Countries
|
Ouoba, Kampadilemba
|
|
|
|
4 |
p. 305-318
|
artikel
|
| 9 |
Embedding Patient-Centricity by Collaborating with Patients to Transform the Rare Disease Ecosystem
|
Sharma, Rohita
|
|
|
|
4 |
p. 265-273
|
artikel
|
| 10 |
EU Compassionate Use Programmes (CUPs)
|
Sou, Hélène
|
|
|
|
4 |
p. 223-229
|
artikel
|
| 11 |
Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials
|
Ushijima, Satoshi
|
|
|
|
4 |
p. 253-260
|
artikel
|
| 12 |
Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality
|
Hashan, Hajed M.
|
|
|
|
4 |
p. 223-231
|
artikel
|
| 13 |
Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives
|
Krendyukov, Andriy
|
|
|
|
4 |
p. 247-256
|
artikel
|
| 14 |
Forum
|
|
|
|
|
4 |
p. 279-290
|
artikel
|
| 15 |
Forum
|
|
|
|
|
4 |
p. 229-239
|
artikel
|
| 16 |
Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions
|
Waschbusch, Max
|
|
|
|
4 |
p. 201-213
|
artikel
|
| 17 |
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
|
Atal, Shubham
|
|
|
|
4 |
p. 223-231
|
artikel
|
| 18 |
Interpersonal Values of Patients Participating in Phase II–III Clinical Trials: Implications for Clinical Trial Representativeness
|
Gouveia, Rita
|
|
|
|
4 |
p. 319-329
|
artikel
|
| 19 |
Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?
|
Nehring, Piotr
|
|
|
|
4 |
p. 257-262
|
artikel
|
| 20 |
Major Pharmaceutical Conferences and Courses
|
|
|
|
|
4 |
p. 291-293
|
artikel
|
| 21 |
Major Pharmaceutical Conferences and Courses: October to November 2022
|
|
|
|
|
4 |
p. 261-264
|
artikel
|
| 22 |
Major Pharmaceutical Conferences and Courses: October to November 2021
|
|
|
|
|
4 |
p. 261-265
|
artikel
|
| 23 |
Major Pharmaceutical Conferences and Courses: October to November 2023
|
|
|
|
|
4 |
p. 335-341
|
artikel
|
| 24 |
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant
|
Phillips-Beyer, Andrea
|
|
|
|
4 |
p. 291-303
|
artikel
|
| 25 |
Patent Cliffs in the Era of Complex Therapies and Biologics
|
Sabatini, Marco T.
|
|
|
|
4 |
p. 271-278
|
artikel
|
| 26 |
Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research
|
Li, Hu
|
|
|
|
4 |
p. 247-259
|
artikel
|
| 27 |
Preparing for the Next Normal: Transformation in the Role of Medical Affairs Following the COVID-19 Pandemic
|
Ghosh, Romik
|
|
|
|
4 |
p. 197-202
|
artikel
|
| 28 |
Tackling Counterfeit Drugs: The Challenges and Possibilities
|
Pathak, Ranjana
|
|
|
|
4 |
p. 281-290
|
artikel
|
| 29 |
75th Annual Meeting of the American Academy of Neurology (AAN 2023)
|
Pochon, Sue
|
|
|
|
4 |
p. 331-334
|
artikel
|
| 30 |
The Central Role of Ethics in Medical Affairs Practice
|
Naraynassamy, Carl
|
|
|
|
4 |
p. 275-279
|
artikel
|
| 31 |
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic
|
Tran, Allan
|
|
|
|
4 |
p. 203-213
|
artikel
|
| 32 |
The NIMH ‘Fast-Fail Trials’ (FAST) Initiative: Rationale, Promise, and Progress
|
Grabb, Margaret C.
|
|
|
|
4 |
p. 233-245
|
artikel
|
| 33 |
Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study
|
Akinola, Samuel
|
|
|
|
4 |
p. 263-269
|
artikel
|
Tijdschrift beschrijving